KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Payables (2020 - 2025)

Historic Payables for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • AbCellera Biologics' Payables fell 121.99% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 121.99%. This contributed to the annual value of $55.0 million for FY2024, which is 1093.99% up from last year.
  • AbCellera Biologics' Payables amounted to $53.1 million in Q3 2025, which was down 121.99% from $50.1 million recorded in Q2 2025.
  • AbCellera Biologics' Payables' 5-year high stood at $55.0 million during Q4 2024, with a 5-year trough of $13.3 million in Q1 2021.
  • Moreover, its 5-year median value for Payables was $42.9 million (2024), whereas its average is $38.5 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 11482.16% in 2023, then crashed by 1611.41% in 2024.
  • Quarter analysis of 5 years shows AbCellera Biologics' Payables stood at $32.0 million in 2021, then surged by 63.97% to $52.5 million in 2022, then fell by 5.56% to $49.6 million in 2023, then increased by 10.94% to $55.0 million in 2024, then decreased by 3.43% to $53.1 million in 2025.
  • Its last three reported values are $53.1 million in Q3 2025, $50.1 million for Q2 2025, and $47.8 million during Q1 2025.